David Spigel, MD | Authors

Articles

Fostering Excellence in Care and Outcomes in Patients With Stage III and IV NSCLC

June 27, 2019

David Spigel, MD, chief scientific officer, Sarah Cannon Research Institute, director of the Lung cancer Research Program, and member of the Association of Community Cancer Centers explains to Targeted Oncology, the ways in which ACCC is improving the care landscape and outcomes for patients with advanced non–small cell lung cancer.

Examining Recent PACIFIC Trial Updates for Durvalumab in Locally Advanced NSCLC

June 19, 2019

David Spigel, MD, chief scientific officer of Sarah Cannon Research Institute, gives a recap on the phase III PACIFIC study, with facts and perceptions surrounding the latest data that study researchers reported during the 2019 ASCO Annual Meeting.

ACCC Addresses Education Needs for Community Oncologists

June 18, 2019

David Spigel, MD, chief scientific officer, Sarah Cannon Research Institute, discussed with Targeted Oncologyat the 2019 ASCO Annual Meeting how the Association of Community Cancer Centers (ACCC) is the change agent for helping physicians provide their patients with quality care.

Updated Results for PACIFIC Trial Establish New Standard of Care in Lung Cancer

September 27, 2018

David Spigel, MD, medical oncologist and Chief Scientific Officer at Sarah Cannon Research Institute, discusses the updated results for the PACIFIC trial, a randomized phase III trial investigating the addition of durvalumab (Imfinzi) to chemoradiation versus placebo in patients with unresectable stage III lung cancer.